Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Current Hepatology Reports
Erschienen in: Current Hepatology Reports 3/2017

22.07.2017 | Portal Hypertension (J Abraldes and E Tsochatzis, Section Editors)

Patient Selection for Transjugular Intrahepatic Portosystemic Stent Shunt (TIPSS) Insertion in Variceal Bleeding and Refractory Ascites

verfasst von: A. Dhaliwal, M. J. Armstrong, D. Tripathi

Erschienen in: Current Hepatology Reports | Ausgabe 3/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose of the Review

Transjugular intrahepatic portosystemic stent shunt (TIPSS) is used to treat the complications of portal hypertension. Patient selection prior to TIPSS remains paramount for survival. This review aims to summarise the key clinical steps in patient selection prior to TIPSS and how patient selection has evolved over the last 5 years.

Recent Findings

Model for End-Stage Liver Disease (MELD) and Child-Pugh scoring in combination remain good predictors of clinical outcome post TIPSS. Minimal hepatic encephalopathy remains a diagnostic challenge, and further testing should be implemented in elective assessment. Portal vein thrombosis is no longer an absolute contraindication. The importance of diastolic dysfunction pre TIPSS remains controversial, and at present echocardiography is only recommended in patients with preexisting cardiac disease, cardiac symptoms and/or incidental abnormal ECG.

Summary

A combination of MELD, Child-Pugh, age, encephalopathy and liver imaging remain key in assessing risk pre TIPSS. A multidisciplinary team approach should be adopted for patient selection.
Literatur
1.
•• Bureau C, Thabut D, Oberti F, Dharancy S, Carbonell N, Bouvier A, et al. Transjugular intrahepatic portosystemic shunts with covered stents increase transplant-free survival of patients with cirrhosis and recurrent ascites. Gastroenterology. 2017;152(1):157–63. A prospective study comparing 1-year transplant-free survival outcome of large-volume paracentesis versus covered TIPSS for refractory ascites.PubMedCrossRef
2.
Suhocki PV, Lungren MP, Kapoor B, Kim CY. Transjugular intrahepatic portosystemic shunt complications: prevention and management. Semin Intervent Radiol. 2015;32(2):123–32.PubMedPubMedCentralCrossRef
3.
Fernandez M. Molecular pathophysiology of portal hypertension. Hepatology. 2015;61(4):1406–15.PubMedCrossRef
4.
Garcia-Pagan JC, Di Pascoli M, Caca K, Laleman W, Bureau C, Appenrodt B, et al. Use of early-TIPS for high-risk variceal bleeding: results of a post-RCT surveillance study. J Hepatol. 2013;58(1):45–50.PubMedCrossRef
5.
Colle I, Geerts AM, Van Steenkiste C, Van Vlierberghe H. Hemodynamic changes in splanchnic blood vessels in portal hypertension. Anat Rec (Hoboken). 2008;291(6):699–713.CrossRef
6.
Lotterer E, Wengert A, Fleig WE. Transjugular intrahepatic portosystemic shunt: short-term and long-term effects on hepatic and systemic hemodynamics in patients with cirrhosis. Hepatology. 1999;29(3):632–9.PubMedCrossRef
7.
Busk TM, Bendtsen F, Moller S. Cardiac and renal effects of a transjugular intrahepatic portosystemic shunt in cirrhosis. Eur J Gastroenterol Hepatol. 2013;25(5):523–30.PubMedCrossRef
8.
Boyer TD, Haskal ZJ. American Association for the Study of Liver D. The role of Transjugular Intrahepatic Portosystemic Shunt (TIPS) in the management of portal hypertension: update 2009. Hepatology. 2010;51(1):306.PubMedCrossRef
9.
de Franchis R, Baveno VIF. Expanding consensus in portal hypertension: report of the Baveno VI Consensus Workshop: stratifying risk and individualizing care for portal hypertension. J Hepatol. 2015;63(3):743–52.PubMedCrossRef
10.
Parvinian A, Shah KD, Couture PM, Minocha J, Knuttinen MG, Bui JT, et al. Older patient age may predict early mortality after transjugular intrahepatic portosystemic shunt creation in individuals at intermediate risk. J Vasc Interv Radiol. 2013;24(7):941–6.PubMedCrossRef
11.
Luca A, Miraglia R, Maruzzelli L, D'Amico M, Tuzzolino F. Early liver failure after transjugular intrahepatic portosystemic shunt in patients with cirrhosis with model for end-stage liver disease score of 12 or less: incidence, outcome, and prognostic factors. Radiology. 2016;280(2):622–9.PubMedCrossRef
12.
D'Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol. 2006;44(1):217–31.PubMedCrossRef
13.
• Zhou C, Hou C, Cheng D, Tang W, Lv W. Predictive accuracy comparison of MELD and Child-Turcotte-Pugh scores for survival in patients underwent TIPS placement: a systematic meta-analytic review. Int J Clin Exp Med. 2015;8(8):13464–72. This study confirms MELD scoring is better than Childs-Pugh scoring to assess overall prognosis after TIPSS, especially at 3 months.PubMedPubMedCentral
14.
Gaba RC, Couture PM, Bui JT, Knuttinen MG, Walzer NM, Kallwitz ER, et al. Prognostic capability of different liver disease scoring systems for prediction of early mortality after transjugular intrahepatic portosystemic shunt creation. J Vasc Interv Radiol. 2013;24(3):411–20. 20 e1-4; quiz 21PubMedCrossRef
15.
Corbett C, Murphy N, Olliff S, Mangat KS, Tripathi D. A case-control study of transjugular intrahepatic portosystemic stent shunts for patients admitted to intensive care following variceal bleeding. Eur J Gastroenterol Hepatol. 2013;25(3):344–51.PubMedCrossRef
16.
Salerno F, Camma C, Enea M, Rossle M, Wong F. Transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis of individual patient data. Gastroenterology. 2007;133(3):825–34.PubMedCrossRef
17.
Malinchoc M, Kamath PS, Gordon FD, Peine CJ, Rank J, ter Borg PC. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology. 2000;31(4):864–71.PubMedCrossRef
18.
19.
Turcotte JG, Child CG 3rd. Portal hypertension. Pathogenesis, management and prognosis. Postgrad Med. 1967;41(1):93–102.PubMedCrossRef
20.
Christensen E. Prognostic models including the Child-Pugh, MELD and Mayo risk scores—where are we and where should we go? J Hepatol. 2004;41(2):344–50.PubMedCrossRef
21.
Saugel B, Phillip V, Gaa J, Berger H, Lersch C, Schultheiss C, et al. Advanced hemodynamic monitoring before and after transjugular intrahepatic portosystemic shunt: implications for selection of patients—a prospective study. Radiology. 2012;262(1):343–52.PubMedCrossRef
22.
Hernandez-Gea V, Procopet B, Giraldez A, Amitrano L, Villanueva C, Thabut D, et al. Early-TIPS improves survival in high-risk variceal bleeders. Results of a Multicenter Variceal Bleeding Observational Study. Hepatology. 2016;64:47A–8A.CrossRef
23.
Manzano-Robleda Mdel C, Barranco-Fragoso B, Uribe M, Mendez-Sanchez N. Portal vein thrombosis: what is new? Ann Hepatol. 2015;14(1):20–7.PubMed
24.
Stine JG, Shah PM, Cornella SL, Rudnick SR, Ghabril MS, Stukenborg GJ, et al. Portal vein thrombosis, mortality and hepatic decompensation in patients with cirrhosis: a meta-analysis. World J Hepatol. 2015;7(27):2774–80.PubMedPubMedCentralCrossRef
25.
Han G, Qi X, He C, Yin Z, Wang J, Xia J, et al. Transjugular intrahepatic portosystemic shunt for portal vein thrombosis with symptomatic portal hypertension in liver cirrhosis. J Hepatol. 2011;54(1):78–88.PubMedCrossRef
26.
• Qi X, Han G, Fan DM. Management of portal vein thrombosis in liver cirrhosis. Nat Rev Gastroenterol Hepatol. 2014;11(7):435–46. An updated review on portal vein thrombosis management highlighting the consideration of TIPSS as a potential treatment option.PubMedCrossRef
27.
Bai M, Qi X, Yang Z, Yin Z, Nie Y, Yuan S, et al. Predictors of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt in cirrhotic patients: a systematic review. J Gastroenterol Hepatol. 2011;26(6):943–51.PubMedCrossRef
28.
• American Association for the Study of Liver D. European Association for the Study of the L. Hepatic encephalopathy in chronic liver disease: 2014 practice guideline by the European Association for the Study of the Liver and the American Association for the Study of Liver Diseases. J Hepatol. 2014;61(3):642–59. Clear guidelines on diagnostic and management strategies for hepatic encephalopathy.CrossRef
29.
Bajaj JS. Review article: the modern management of hepatic encephalopathy. Aliment Pharmacol Ther. 2010;31(5):537–47.PubMedCrossRef
30.
Jalan R, Forrest EH, Redhead DN, Dillon JF, Hayes PC. Reduction in renal blood flow following acute increase in the portal pressure: evidence for the existence of a hepatorenal reflex in man? Gut. 1997;40(5):664–70.PubMedPubMedCentralCrossRef
31.
Narahara Y, Kanazawa H, Fukuda T, Matsushita Y, Harimoto H, Kidokoro H, et al. Transjugular intrahepatic portosystemic shunt versus paracentesis plus albumin in patients with refractory ascites who have good hepatic and renal function: a prospective randomized trial. J Gastroenterol. 2011;46(1):78–85.PubMedCrossRef
32.
Tan HK, James PD, Sniderman KW, Wong F. Long-term clinical outcome of patients with cirrhosis and refractory ascites treated with transjugular intrahepatic portosystemic shunt insertion. J Gastroenterol Hepatol. 2015;30(2):389–95.PubMedCrossRef
33.
Schepke M, Roth F, Koch L, Heller J, Rabe C, Brensing KA, et al. Prognostic impact of renal impairment and sodium imbalance in patients undergoing transjugular intrahepatic portosystemic shunting for the prevention of variceal rebleeding. Digestion. 2003;67(3):146–53.PubMedCrossRef
34.
35.
Rossle M, Gerbes AL. TIPS for the treatment of refractory ascites, hepatorenal syndrome and hepatic hydrothorax: a critical update. Gut. 2010;59(7):988–1000.PubMedCrossRef
36.
37.
Grose RD, Nolan J, Dillon JF, Errington M, Hannan WJ, Bouchier IA, et al. Exercise-induced left ventricular dysfunction in alcoholic and non-alcoholic cirrhosis. J Hepatol. 1995;22(3):326–32.PubMedCrossRef
38.
Rabie RN, Cazzaniga M, Salerno F, Wong F. The use of E/A ratio as a predictor of outcome in cirrhotic patients treated with transjugular intrahepatic portosystemic shunt. Am J Gastroenterol. 2009;104(10):2458–66.PubMedCrossRef
39.
Cazzaniga M, Salerno F, Pagnozzi G, Dionigi E, Visentin S, Cirello I, et al. Diastolic dysfunction is associated with poor survival in patients with cirrhosis with transjugular intrahepatic portosystemic shunt. Gut. 2007;56(6):869–75.PubMedPubMedCentralCrossRef
40.
• Shounak M, Vimal R, Colin S, David IS. A retrospective analysis of the impact of diastolic dysfunction on one-year mortality after transjugular intrahepatic porto-systemic shunt, liver transplantation and non-transplant abdominal surgery in patients with cirrhosis. Ann Gastroenterol. 2015;28(3):385–90. This study highlights that presence of diastolic dysfunction is not associated with increased 1-year mortality in patients with cirrhosis undergoing transjugular intrahepatic porto-systemic shunt or abdominal surgeries including liver transplantation.PubMedPubMedCentral
41.
Ruiz-del-Arbol L, Achecar L, Serradilla R, Rodriguez-Gandia MA, Rivero M, Garrido E, et al. Diastolic dysfunction is a predictor of poor outcomes in patients with cirrhosis, portal hypertension, and a normal creatinine. Hepatology. 2013;58(5):1732–41.PubMedCrossRef
42.
Nagueh SF, Appleton CP, Gillebert TC, Marino PN, Oh JK, Smiseth OA, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. J Am Soc Echocardiogr. 2009;22(2):107–33.PubMedCrossRef
43.
Armstrong MJ, Gohar F, Baker G, Nightingale P, Greaves D, Dhaliwal A, et al. Echocardiography in patients with cirrhosis does not predict the clinical outcome after Transjugular Intrahepatic Portosystemic Stent-Shunt (TIPSS). J Hepatol. 2017;66(1; Supplement):S381.CrossRef
44.
Tsien C, Shah SN, McCullough AJ, Dasarathy S. Reversal of sarcopenia predicts survival after a transjugular intrahepatic portosystemic stent. Eur J Gastroenterol Hepatol. 2013;25(1):85–93.PubMedCrossRef
45.
Nardelli S, Lattanzi B, Torrisi S, Greco F, Farcomeni A, Gioia S, et al. Sarcopenia is risk factor for development of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt placement. Clin Gastroenterol Hepatol. 2017;15(6):934–6.PubMedCrossRef
Metadaten
Titel
Patient Selection for Transjugular Intrahepatic Portosystemic Stent Shunt (TIPSS) Insertion in Variceal Bleeding and Refractory Ascites
verfasst von
A. Dhaliwal
M. J. Armstrong
D. Tripathi
Publikationsdatum
22.07.2017
Verlag
Springer US
Erschienen in
Current Hepatology Reports / Ausgabe 3/2017
Elektronische ISSN: 2195-9595
DOI
https://doi.org/10.1007/s11901-017-0361-y

Weitere Artikel der Ausgabe 3/2017

Current Hepatology Reports 3/2017 Zur Ausgabe

Portal Hypertension (J Abraldes and E Tsochatzis, Section Editors)

Cardiovascular Effects of a Transjugular Intrahepatic Portosystemic Shunt in Patients with Cirrhosis

Hepatitis B (J Lim, Section Editor)

Epidemiology and Treatment of Hepatitis B in Prisoners

Hepatitis C (J Ahn and A Aronsohn, Section Editors)

Next-Generation Direct-Acting Antiviral Drug-Based Regimens for Hepatitis C

Portal Hypertension (J Abraldes and E Tsochatzis, Section Editors)

Idiopathic Non-cirrhotic Portal Hypertension and Close Entities: a Need for Clarifying Terminology

Portal Hypertension (J Abraldes and E Tsochatzis, Section Editors)

Risk Stratification with Noninvasive Tools in Patients with Compensated Cirrhosis

Management of the Cirrhotic Patient (A Cardenas and N Reau, Section Editors)

Current Trends in the Management of Spontaneous Bacterial Peritonitis

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise